PTC Therapeutics Inc. (PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwe...

The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

PTCT Earnings Beat but Sales Drop 4%

PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st...

The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.'s PTCT SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).

PTC Therapeutics, Inc. PTCT announced it has gained FDA approval for SEPHIENCE on Monday.

The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder that prevents the body from properly breaking down certain amino acids, the ...

LOS ANGELES--(BUSINESS WIRE)---- $PTCT--PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.